191 related articles for article (PubMed ID: 18794098)
1. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Goetz MP; Suman VJ; Couch FJ; Ames MM; Rae JM; Erlander MG; Ma XJ; Sgroi DC; Reynolds CA; Lingle WL; Weinshilboum RM; Flockhart DA; Desta Z; Perez EA; Ingle JN
Clin Cancer Res; 2008 Sep; 14(18):5864-8. PubMed ID: 18794098
[TBL] [Abstract][Full Text] [Related]
2. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
Jansen MP; Sieuwerts AM; Look MP; Ritstier K; Meijer-van Gelder ME; van Staveren IL; Klijn JG; Foekens JA; Berns EM
J Clin Oncol; 2007 Feb; 25(6):662-8. PubMed ID: 17308270
[TBL] [Abstract][Full Text] [Related]
3. HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
Habel LA; Sakoda LC; Achacoso N; Ma XJ; Erlander MG; Sgroi DC; Fehrenbacher L; Greenberg D; Quesenberry CP
Breast Cancer Res; 2013 Mar; 15(2):R24. PubMed ID: 23497539
[TBL] [Abstract][Full Text] [Related]
4. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen.
Goetz MP; Suman VJ; Ingle JN; Nibbe AM; Visscher DW; Reynolds CA; Lingle WL; Erlander M; Ma XJ; Sgroi DC; Perez EA; Couch FJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2080-7. PubMed ID: 16609019
[TBL] [Abstract][Full Text] [Related]
5. Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome.
Jerevall PL; Brommesson S; Strand C; Gruvberger-Saal S; Malmström P; Nordenskjöld B; Wingren S; Söderkvist P; Fernö M; Stål O
Breast Cancer Res Treat; 2008 Jan; 107(2):225-34. PubMed ID: 17453342
[TBL] [Abstract][Full Text] [Related]
6. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
Ma XJ; Hilsenbeck SG; Wang W; Ding L; Sgroi DC; Bender RA; Osborne CK; Allred DC; Erlander MG
J Clin Oncol; 2006 Oct; 24(28):4611-9. PubMed ID: 17008703
[TBL] [Abstract][Full Text] [Related]
7. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
8. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
9. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
Ma XJ; Salunga R; Dahiya S; Wang W; Carney E; Durbecq V; Harris A; Goss P; Sotiriou C; Erlander M; Sgroi D
Clin Cancer Res; 2008 May; 14(9):2601-8. PubMed ID: 18451222
[TBL] [Abstract][Full Text] [Related]
10. Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.
Zhao L; Zhu S; Gao Y; Wang Y
Tumour Biol; 2014 Apr; 35(4):3113-7. PubMed ID: 24264313
[TBL] [Abstract][Full Text] [Related]
11. Association of miR-1266 with recurrence/metastasis potential in estrogen receptor positive breast cancer patients.
Sevinc ED; Egeli U; Cecener G; Tezcan G; Tunca B; Gokgoz S; Tasdelen I; Tolunay S; Evrensel T
Asian Pac J Cancer Prev; 2015; 16(1):291-7. PubMed ID: 25640367
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Goetz MP; Rae JM; Suman VJ; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Flockhart DA; Desta Z; Perez EA; Ingle JN
J Clin Oncol; 2005 Dec; 23(36):9312-8. PubMed ID: 16361630
[TBL] [Abstract][Full Text] [Related]
14. The prognostic biomarkers HOXB13, IL17BR, and CHDH are regulated by estrogen in breast cancer.
Wang Z; Dahiya S; Provencher H; Muir B; Carney E; Coser K; Shioda T; Ma XJ; Sgroi DC
Clin Cancer Res; 2007 Nov; 13(21):6327-34. PubMed ID: 17975144
[TBL] [Abstract][Full Text] [Related]
15. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.
Jerevall PL; Jansson A; Fornander T; Skoog L; Nordenskjöld B; Stål O
Breast Cancer Res; 2010; 12(4):R53. PubMed ID: 20649975
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.
Sgroi DC; Chapman JA; Badovinac-Crnjevic T; Zarella E; Binns S; Zhang Y; Schnabel CA; Erlander MG; Pritchard KI; Han L; Shepherd LE; Goss PE; Pollak M
Breast Cancer Res; 2016 Jan; 18(1):1. PubMed ID: 26728744
[TBL] [Abstract][Full Text] [Related]
17. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
Xu Y; Sun Y; Yao L; Shi L; Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; He L; Li P; Xie Y
Ann Oncol; 2008 Aug; 19(8):1423-1429. PubMed ID: 18407954
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy.
Kiyotani K; Mushiroda T; Sasa M; Bando Y; Sumitomo I; Hosono N; Kubo M; Nakamura Y; Zembutsu H
Cancer Sci; 2008 May; 99(5):995-9. PubMed ID: 18294285
[TBL] [Abstract][Full Text] [Related]
19. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM; Carey LA; McLeod HL
Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
